The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INDV | +216.19% | +272.93% | +30.1% | +199% |
| S&P | +19.17% | +69.21% | +11.09% | +219% |
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.
This fund just doubled down on a stock that’s suddenly delivering the earnings momentum it’s promised for years.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $358.00M | 20.1% |
| Gross Profit | $294.00M | 1.0% |
| Gross Margin | 82.12% | -15.5% |
| Market Cap | $4.48B | 187.5% |
| Market Cap / Employee | $5.34M | 0.0% |
| Employees | 838 | -20.3% |
| Net Income | $102.00M | 410.0% |
| EBITDA | $127.00M | 27.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $195.00M | -38.9% |
| Accounts Receivable | $253.00M | -0.4% |
| Inventory | 153 | -14.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $312.00M | -10.1% |
| Short Term Debt | $39.00M | 39.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 16.53% | 18.7% |
| Return On Invested Capital | -75.35% | -77.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$249,866.29K | -1062.5% |
| Operating Free Cash Flow | -$226,375.90K | -3908.5% |
| Metric | Q1 2024 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 516.14 | 20.80 | 24.00 | 21.61 | - |
| Price to Book | -3.42 | -6.46 | -11.73 | -21.67 | 124.66% |
| Price to Sales | 1.02 | 1.58 | 2.64 | 3.62 | 176.55% |
| Price to Tangible Book Value | -3.37 | -6.31 | -11.42 | -21.46 | 375.66% |
| Price to Free Cash Flow TTM | 221.31 | 8.89 | 9.36 | 23.12 | - |
| Enterprise Value to EBITDA | 16.28 | 23.15 | 29.05 | 36.54 | 126.35% |
| Free Cash Flow Yield | 0.5% | 11.3% | 10.7% | 4.3% | - |
| Return on Equity | 12.2% | - | |||
| Total Debt | $370.00M | $366.00M | $356.00M | $351.00M | -6.40% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
